RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications

PLoS One. 2015 Jun 3;10(6):e0128686. doi: 10.1371/journal.pone.0128686. eCollection 2015.

Abstract

The inhibitory potency of an antisense oligonucleotide depends critically on its design and the accessibility of its target site. Here, we used an RNA interference-guided approach to select antisense oligonucleotide target sites in the coding region of the highly structured hepatitis C virus (HCV) RNA genome. We modified the conventional design of an antisense oligonucleotide containing locked nucleic acid (LNA) residues at its termini (LNA/DNA gapmer) by inserting 8-oxo-2'-deoxyguanosine (8-oxo-dG) residues into the central DNA region. Obtained compounds, designed with the aim to analyze the effects of 8-oxo-dG modifications on the antisense oligonucleotides, displayed a unique set of properties. Compared to conventional LNA/DNA gapmers, the melting temperatures of the duplexes formed by modified LNA/DNA gapmers and DNA or RNA targets were reduced by approximately 1.6-3.3°C per modification. Comparative transfection studies showed that small interfering RNA was the most potent HCV RNA replication inhibitor (effective concentration 50 (EC50): 0.13 nM), whereas isosequential standard and modified LNA/DNA gapmers were approximately 50-fold less efficient (EC50: 5.5 and 7.1 nM, respectively). However, the presence of 8-oxo-dG residues led to a more complete suppression of HCV replication in transfected cells. These modifications did not affect the efficiency of RNase H cleavage of antisense oligonucleotide:RNA duplexes but did alter specificity, triggering the appearance of multiple cleavage products. Moreover, the incorporation of 8-oxo-dG residues increased the stability of antisense oligonucleotides of different configurations in human serum.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Base Pairing
  • Cell Line, Tumor
  • Deoxyguanosine / analogs & derivatives*
  • Deoxyguanosine / chemistry
  • Genome, Viral*
  • Hepacivirus / genetics*
  • Hepacivirus / growth & development
  • Hepatocytes / metabolism
  • Hepatocytes / virology
  • Humans
  • Molecular Targeted Therapy
  • Oligonucleotides / chemistry*
  • Oligonucleotides / metabolism
  • Oligonucleotides, Antisense / chemical synthesis
  • Oligonucleotides, Antisense / genetics*
  • Oligonucleotides, Antisense / metabolism
  • RNA Cleavage
  • RNA Interference
  • RNA Stability
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • RNA, Viral / antagonists & inhibitors*
  • RNA, Viral / genetics
  • RNA, Viral / metabolism
  • Structure-Activity Relationship
  • Virus Replication

Substances

  • Oligonucleotides
  • Oligonucleotides, Antisense
  • RNA, Small Interfering
  • RNA, Viral
  • locked nucleic acid
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine

Grants and funding

Estonian Enterprise grant “OLIGO-MOD” (MKarelson) European Regional Development Fund through the Centre of Excellence in Chemical Biology (AM) European Regional Development Fund project 3.2.0701.11-0016 “HCV-TECH” (AM) Estonian Ministry of Education and Research grants SF0140031As09 (MKarelson) and SF0180087s08 (AM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Co-authors AP, TR, MM, AN, LV, EZ, M. Kelve and M. Karelson were employed by GeneCode, Ltd at some period of time when the work results of which have been included into this manuscript was in progress. GeneCode, Ltd. provided support in the form of salaries for authors AP, TR, MM, AN, LV, EŽ and M. Kelve, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.